Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - addendum

Prepared by Liverpool Reviews & Implementation Group, University of Liverpool.

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - addendum

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - addendum
15 June 2012
(416.63 Kb 1 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 14 June 2012